Source comparison
MOTS-c vs Tesofensine: Comparison
Mechanism Mitochondrial-derived peptide; activates AMPK to improve insulin sensitivity and mitochondrial function Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin); suppresses appetite centrally MOTS-c is metabolic recalibration; tesofe
This comparison does not assign a generated winner or score.
- Mechanism
- Mitochondrial-derived peptide; activates AMPK to improve insulin sensitivity and mitochondrial function
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin); suppresses appetite centrally
- MOTS-c is metabolic recalibration; tesofensine is appetite suppression
- Primary Pathway
- AMPK activation → enhanced fat oxidation, glucose uptake, mitochondrial biogenesis
- CNS monoamine modulation → reduced food intake, prolonged satiety signaling
- Different biological systems. Not directly comparable
- Weight Loss Evidence
- Limited human data; rodent studies show improved metabolism without significant weight loss
- Phase III human trials: 12.8% mean body weight reduction at 24 weeks (1.0mg dose)
- Tesofensine has stronger direct weight loss evidence
- Research Application
- Metabolic disease, insulin resistance, mitochondrial dysfunction, aging research
- Appetite regulation, CNS satiety pathways, obesity pharmacology
- Choose based on biological system under study
- Side Effect Profile
- Minimal reported adverse events in animal studies; human data insufficient
- Nausea (30–40%), increased heart rate (+7 bpm), dry mouth, constipation
- MOTS-c appears better tolerated but lacks long-term human data
- Storage Stability
- Lyophilized: −20°C; reconstituted: 2–8°C, use within 28 days
- More stable; lyophilized form room-temperature stable for months
- Tesofensine easier to handle in research settings